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ABSTRACT 
Background. Improvement in long-term renal allograft survival is impeded by incomplete or 
erroneous coding of causes of allograft loss. This study reports 13-year trends in causes of 
graft failure across the UK. 
Methods. National Health Service Blood and Transplant (NHSBT) and UK Renal Registry data 
were linked to describe UK kidney patients transplanted 2000–2013. NHSBT graft failure 
categories were used, with ‘other’ recoded when free text was available. Adjusted analyses 
examined the influence of age, ethnicity and donor type on causes of graft failure. 
Results. In 22,730 recipients, 5,389 (23.7%) grafts failed within a median follow-up of five 
years. The two most frequent causes were death with a functioning graft (40.8%) and 
alloimmune pathology (25.0%). Graft survival was higher in recipients who were younger 
(mean 47.3 vs. 50.7 years), received a pre-emptive transplant (20.2% vs. 10.4%), spent less 
time on dialysis (median 1.6 vs. 2.4 years) and received a living donor transplant (36.3% vs. 
22.2%), with no differences by sex, ethnicity or human leukocyte antigen mismatch. 
Allograft failure within two years of transplantation fell from 12.5% (2000–2004) to 9.8% 
(2009–2013). Surgical and alloimmune related failures decreased over time while death with 
a functioning graft became more common. Age, ethnicity and donor type were factors in 
recurrent primary disease and alloimmune pathology. 
Conclusions. Since 2000 there have been reductions in surgical and alloimmune graft 
failures in the UK. However, graft failure codes need to be revised if they are to remain 
useful and effective in epidemiological and quality improvement trials. 
 
Keywords: epidemiology, graft failure, kidney transplant 
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INTRODUCTION 
Allogeneic renal transplantation is the treatment of choice for end-stage kidney disease, 
offering superior outcomes in terms of morbidity and mortality when compared to dialysis 
[1, 2]. However, kidney transplants do not survive the lifespan of most recipients [3] and 
approximately 840 patients return to dialysis each year in the United Kingdom (UK) [4]. This 
makes allograft failure the fifth most common reason for people to start dialysis in the UK 
[5], while in the United States (US), allograft failure is the fourth most common reason [6]. 
Over the past decades there have unquestionably been great improvements in renal 
transplant survival in the first year post-transplantation [3]. However, there have not been 
similar improvements in outcomes beyond the first year. One of the major unmet needs in 
renal transplantation is to improve longer term allograft survival. A significant barrier to 
progress in this area is incomplete or erroneous understanding of the causes of longer term 
allograft loss.  
Surprisingly few studies have reported causes of longer term graft loss, particularly for UK 
recipients. One large US study by El-Zoghby et al. [7] retrospectively analysed clinical and 
histological information for 1,317 kidney recipients, with a mean follow-up of 50 months. A 
quarter of grafts were lost over this time: 10.4% due to death with a functioning graft; 2.9% 
a result of primary non-function; and 11.6% due to death censored graft failure. This latter 
group was subdivided for cause: 36.6% glomerular diseases; 30.7% fibrosis/atrophy; 16.3% 
medical/surgical conditions; 11.8% acute rejection; and 4.6% unclassifiable. Glomerular 
pathologies included recurrent disease (23/56), transplant glomerulopathy (23/56) and 
presumed non-recurrent disease (10/56). Fibrosis/atrophy was only attributed to calcineurin 
inhibitor toxicity in one patient.  
More recently, Sellarés et al. [8] prospectively studied 315 North American recipients after 
indication biopsies, 60 of whom progressed to graft failure at a median of 31.4 months. 
They undertook to explain each failure using biopsy diagnoses, human leukocyte antigen 
(HLA) antibody data and clinical information. Excluding four patients with missing 
information, failure was attributed to four main causes: 64.3% rejection; 17.9% 
glomerulonephritis; 7.1% polyoma virus nephropathy; and 10.7% intercurrent events. The 
heterogeneity of these data hints at the difficulties in assigning a precise cause for allograft 
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loss. However, differences in practice, for example in immune suppression regimens, mean 
that reasons for graft failure in the US cannot directly be extrapolated to Europe. 
In this paper, we present outcome data for UK kidney recipients transplanted between 2000 
and 2013. To date, this is the largest cohort of renal allograft losses reported worldwide and 
the first such study from the UK. This study forms a basis for future investigations and 
interventions to improve transplant outcomes. 
 
MATERIALS AND METHODS 
Study population 
The study population included incident renal allograft recipients from 1 January 2000 to 31 
December 2013, who met the following inclusion criteria: aged ≥18 years at the time of 
transplant; receiving a single organ transplant; receiving their first transplant; and 
transplanted at a UK renal centre reporting to the UK Renal Registry (UKRR) at the time of 
transplantation. The study population was restricted to those transplanted after 2000 
because preliminary analysis of the entire National Health Service Blood and Transplant 
(NHSBT) dataset from 1983 established that the proportion of missing data prior to 2000 
approached 40%. Patients were followed to 31 December 2014. 
Dataset 
Data were provided by both the UKRR and NHSBT; NHSBT data were linked to the patient 
cohort identified from UKRR data. This linkage ensured that all graft losses were captured, 
whether recorded as a lost graft or as a return to dialysis. 
Revision of cause of graft failure categories 
The historical NHSBT categories for causes of graft failure were as follows: hyperacute 
rejection; rejection whilst taking immunosuppressive drug(s); rejection after stopping all 
immunosuppressive drugs; recurrent primary renal disease; vascular or ureteric operative 
problems (excluding vascular thrombosis); vascular (arterial or venous) thrombosis; 
infection of graft; removal of functioning graft; non-viable kidney; other; and missing. We 
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deemed these categories insufficiently informative and to enable more meaningful 
reporting revised them as detailed in Box 1. 
Refining the documented cause of graft failure 
More than 600 graft losses were recorded by NHSBT as due to ‘other’ causes, with an 
accompanying free text entry supplied by the recipient’s local renal unit. On reviewing the 
free text entries, it became apparent that a large number corresponded to more specific 
NHSBT coding categories. To improve the accuracy of the final dataset these losses originally 
recorded as ‘other’ were recoded independently by three researchers (HB, FC, RH). Any 
discrepancies were discussed amongst the study group until a consensus decision was 
reached. This process resulted in the reallocation of 59% of ‘other’ causes of graft loss to 
more specific graft failure categories. In addition, this process permitted the identification of 
common subcategories within ‘other’ (Box 1). These data provide an interesting insight into 
the range of pathological processes that can result in graft loss. In cases where the meaning 
of the free text was unclear, the cause of graft loss was assigned as ‘other – miscellaneous’. 
Furthermore, the range of time to graft failure was examined within each category to 
highlight erroneous coding, for example, one graft failure >2,000 days post-transplant that 
had been coded as ‘hyperacute rejection’. 
Statistical analysis 
Percentages were presented for categorical variables while medians and interquartile 
ranges were presented for the continuous variables not normally distributed. Means and 
standard variations were presented for continuous and normally distributed variables. 
Analyses were based on the overall period of 2000–2013 as well as on separate cohorts 
2000–2004, 2005–2008 and 2009–2013 to enable the investigation of trends. Data were 
censored at two years for some analyses comparing the cohorts, because some types of 
failure are more likely earlier than others and because the different cohorts have different 
durations of follow-up.  
Multinomial logistic regression models were developed for the subgroup of patients whose 
grafts failed to identify the influence of patient specific variables including time to failure, 
transplant era, donor age, ethnicity, donor type and HLA mismatch on the probability of 
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having each cause of graft failure. All the models were adjusted for donor age, sex, primary 
renal disease (PRD) and ethnicity. These variables were clinically significant so we adjusted 
for them even in the case that they did not achieve statistical significance. The obtained 
predicted probabilities were presented in tables and graphs. There was a very low 
percentage of missing data and these were omitted from the statistical analyses, apart from 
missing data for the cause of graft failure which were categorised as ‘missing’. P-values were 
only considered for pre-specified hypotheses to avoid multiple testing and identification of 
spurious associations.  
All analyses were performed using SAS 9.3. The UKRR has permission from the Health 
Research Authority’s Confidentiality Advisory Group (16/CAG/0064) and National Research 
Ethics Service (16/NE/0042) to use data collected without individual patient consent for 
research. 
 
RESULTS 
Study participants 
A total of 22,730 recipients fulfilled the inclusion criteria and received a kidney transplant 
for the first time between 1 January 2000 and 31 December 2013. The median follow-up 
time was approximately five years. Three hundred and eighty-nine patients (1.7%) were lost 
to follow-up in the final dataset used for the cause of graft failure analysis. By the end of the 
follow-up period on 31 December 2014, a total of 5,389 allografts had failed, representing 
23.7% of the study cohort (Figure 1).  
As detailed in Table 1, those recipients whose allografts failed were noted to be older (mean 
age 50.7 vs. 47.3 years), to be less likely to have been transplanted pre-emptively (10.4% vs. 
20.2%) or to have received a kidney from a living donor (22.2% vs. 36.3%) and were more 
likely to have spent longer on dialysis pre-transplant (median 2.4 vs. 1.6 years). However, no 
differences in sex, ethnicity or HLA mismatch were apparent. The spectrum of PRDs was also 
similar, although diabetic renal disease was more frequent in those with a failed allograft. 
Causes of graft failure 
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As detailed in Figure 2, the most frequent cause of allograft failure in this UK cohort was 
death with a functioning graft, representing 40.8% of all grafts lost. The most common 
cause of allograft failure in surviving patients was alloimmune pathology, accounting for a 
further 25.0% of graft losses. Other recorded causes were surgical (8.2%); recurrent primary 
disease (3.5%); non-viable kidney (2.7%); infection of the graft (1.7%); and a variety of other 
pathologies listed in Box 1 (4.9%). Detailed information regarding these ‘other’ causes of 
graft loss are available as supplementary data (Table S1). No cause was recorded for 12.7% 
of failed allografts.  
Causes of graft failure over time 
Figure 3 depicts the total numbers of allografts lost at different time points post-
transplantation and the trends in causes of graft loss over time. A clear difference can be 
seen between the first 12 months post-transplantation and subsequent years. As expected, 
surgical causes are more prominent in the early phase, together with non-viable kidney. 
After the first year, other causes including alloimmune pathology and death with a 
functioning graft become more prominent, but the relative contributions of these other 
causes then remain static over time. 
To investigate whether trends in allograft failure have changed over time, the proportion of 
grafts failing within two years of transplant were compared for different transplant eras, as 
shown in Figure 4. This allows like-for-like comparison between the eras, which otherwise 
would have different durations of follow-up and therefore different causes of graft failure. 
Although the number of transplants performed has increased over time, the proportion of 
grafts failing in the first two years has fallen, from 12.5% of transplants carried out from 
2000–2004, to 9.8% of transplants performed from 2009–2013. As not all centres reported 
to the UKRR prior to 2008, this analysis was repeated, limiting the data to those received 
from centres reporting in all three periods. Similar results were observed (data not shown). 
On the background of this falling overall rate of graft loss by two years, it was also of 
interest to establish if the spectrum of causes of graft failure has changed over time (Figure 
5). The most notable change is a reduction in the proportion lost due to alloimmune 
pathology and surgical cause in the most recent era, 2009–2013, mirrored by an increase in 
proportion lost due to death with a functioning graft. It is conceivable that this represents 
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improvements in immunosuppression regimes and surgical technique. Conversely, it may 
reflect more elderly patients with multiple comorbidities being transplanted between 2009 
and 2013. 
Demographical change over time 
Table 2 explores the differences described above by detailing the demographics of the 
entire cohort according to transplant era. The number of transplants performed overall has 
increased over time. The age of recipients has increased slightly between the 2000–2004 
and 2009–2013 cohorts (mean 46.1 vs. 49.8 years), as has donor age (45.6 vs. 48.4 years). As 
has been well documented elsewhere [9], donation after circulatory death (DCD) has 
steadily increased, with a corresponding reduction in the proportion of organs donated after 
brain death (DBD). Living donor transplantation increased substantially from 24.3% in 2000–
2004 to 34.9% in 2005–2008 and continues to account for more than one third of 
transplants in the most recent transplant era. Pre-emptive transplantation also increased 
over time (11.2% to 21.0%). The proportion of patients from Asian and Black ethnic groups 
has also increased. In contrast, the spectrum of PRDs has remained largely constant. 
Adjusted analyses 
Several adjusted analyses were undertaken to assess the impact of recipient age, donor type 
and ethnicity on causes of allograft failure.  
Table 3 details the spectrum of causes of allograft failure across different age categories 
after adjusting for sex, ethnicity and PRD. Even after adjusting for PRD, recurrent primary 
disease is more prominent as a cause of allograft failure in younger patients. This could be 
due to competing risks in older patients, who are less likely to lose their graft from recurrent 
disease. Alloimmune pathology is also more common in the younger age categories whilst, 
unsurprisingly, death with a functioning graft accounts for the largest proportion of allograft 
losses in the oldest age category. 
Table 4 shows the impact of donor type on cause of allograft failure after adjusting for 
recipient age, sex and PRD. Recipients of a live donor kidney are more likely to have 
recurrent primary disease than patients receiving a kidney from a deceased donor, whilst 
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recipients of a DCD kidney are the most likely to lose their graft from a surgical cause. 
Beyond this, there is an equal distribution of causes across the other categories. 
Table 5 indicates the causes of allograft failure in different ethnic groups after adjusting for 
recipient age, gender and PRD. Alloimmune pathology is more prominent in non-White 
patients, whilst death with a functioning graft is less likely in Black patients. The numbers 
are too small in the remaining categories of causes of graft loss to draw meaningful 
conclusions. 
Figure 6 examines the impact of HLA mismatch on causes of allograft failure. The absolute 
numbers of graft failures by HLA mismatch and era are shown in Figure 7. As might be 
predicted, a lower proportion of alloimmune pathology is seen in patients with a 000 
mismatch. These patients have a corresponding increase in death with a functioning 
graft.Error! Reference source not found. 
DISCUSSION 
Despite significant improvements in one-year kidney allograft survival, the rate of chronic 
graft loss beyond the first year remains substantial, with little improvement over the last 
decade [3]. Therefore, most kidney transplant recipients outlive their allografts and better 
long-term allograft survival remains a major unmet need in kidney transplantation. To 
address this issue requires a better understanding of the causes of long-term allograft loss.  
In this paper, we have assessed allograft outcomes in over 20,000 UK kidney recipients 
transplanted in the modern era of immunosuppression. This includes the largest cohort of 
renal allograft losses so far reported and the only detailed analysis of the causes of renal 
allograft failure in Europe.  
Risk factors for allograft failure 
After a median follow-up of approximately five years, over 5,000 allografts had failed, which 
constituted almost one quarter of the study cohort. Risk factors for allograft failure included 
an older recipient, particularly those older than 55 years, longer time spent on dialysis, 
particularly time in excess of three years, and, unsurprisingly, receipt of a kidney from a 
deceased rather than a living donor. Patients transplanted pre-emptively had a lower 
likelihood of allograft failure (10.4% versus 20.2%). Interestingly, in this UK cohort there was 
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no impact of recipient sex, ethnicity or degree of HLA compatibility on the risk of allograft 
failure, although these are conventionally regarded as factors which influence long-term 
outcomes following kidney transplantation [10]. 
The changing causes of allograft failure over time 
Overall, the two most frequent causes of allograft failure were death with a functioning 
graft, representing 40.8% of all grafts lost and alloimmune pathology, accounting for a 
further 25.0% of graft losses. We assessed trends in causes of graft loss over time, and, not 
unexpectedly, there is a clear difference in the principal causes of graft loss during the first 
six months post-transplantation, where surgical causes and non-viable kidney are 
prominent, and during subsequent years where other causes, including alloimmune 
pathology and death with a functioning graft, become more dominant. Beyond the first year 
after transplantation the proportion of grafts lost to any cause remains relatively constant. 
This may reflect the relatively short duration of follow-up in our study because it is reported 
elsewhere that, for example, recurrent glomerulonephritis after transplantation becomes 
more common with a longer follow-up period [11].  
We also assessed trends in allograft failure across different transplant eras, focusing on the 
first two years after transplantation to enable like-for-like comparison. Reassuringly, the 
overall proportion of grafts failing within the first two years has fallen over time, from 12.5% 
of transplants performed between 2000 and 2004, to 9.8% of transplants performed 
between 2009 and 2013. Against this background, we observed a notable reduction in the 
proportion of grafts lost either due to alloimmune pathology or to surgical causes in the 
most recent era. These welcome trends are likely to reflect advances in surgical practice and 
changes in immunosuppressive protocols. However, they are mirrored by an increase in the 
relative proportion of grafts lost due to death with a functioning graft, which may reflect the 
increasing acceptance of elderly and co-morbid patients as transplant candidates.  
To assess this further we explored the changing demographics of the entire patient cohort 
over time. While the overall number of transplants has increased, donor and recipient age 
has also increased. Donation after circulatory death has also steadily increased, with a 
corresponding reduction in the proportion of organs donated after brain death. We 
observed a substantial increase in the proportion of living donor kidney transplants, which 
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account for approximately one third of all kidney transplants in the most recent era. Rates 
of pre-emptive transplantation have increased, from 11.2% to 21.0%, and the proportion of 
non-White patients has also increased. There has been no change in the spectrum of PRDs.  
Several adjusted analyses were undertaken to assess the impact of donor type, recipient age 
and ethnicity on the causes of graft failure. Unsurprisingly, there is a higher proportion of 
graft loss due to recurrent primary disease and to alloimmune pathology in younger 
patients, whereas older patients are more likely to die with a functioning graft. Recipients of 
a DCD kidney have the highest proportion of graft loss due to surgical causes, whilst 
recipients of a living donor kidney are more likely to lose their grafts due to recurrent 
primary disease than patients receiving a kidney from a deceased donor. This could be 
because living donors are often genetically related to the recipient and so the living donor 
kidney may be more sensitive to the underlying disease than an allograft from a deceased 
donor. Alloimmune pathology is more prominent in non-White patients, while death with a 
functioning graft is less likely in Black patients. As expected, a lower proportion of 
alloimmune pathology is seen in patients with a 000 HLA mismatch. These patients have a 
corresponding increase in death with a functioning graft.  
Strengths and limitations 
This study used a nationally comprehensive prospective cohort of kidney transplant 
recipients to investigate and describe trends in causes of graft failure. The same code list 
has been used throughout by NHSBT and a standardised approach was taken to combine 
these codes into new categories and review and code free-text causes of graft failure, where 
these were provided. Data were not available, however, on whether biopsies had been 
performed and whether the causes given were based on histology. It was also difficult to 
know how clinical teams had interpreted certain codes, such as rejection while taking versus 
after stopping immune suppression medication. We recognise that disease coding without 
clear description results in bias due to a tendency to follow ‘common wisdom’; the ease of 
selecting a predefined category can also hamper accurate data collection. Furthermore, the 
coding system does not allow for multifactorial graft loss, which is common in clinical 
practice. Lastly, the code list in use had not kept pace with developments in understanding 
of allograft immunology and pathology, such as chronic allograft damage due to interstitial 
fibrosis or tubular atrophy [12]. While we have cleaned and validated the UK cause of graft 
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failure as much as possible, we feel there is a real need to revise the code list. This might 
require the development of a new coding system, like the one developed by the European 
Renal Association–European Dialysis and Transplant Association (ERA-EDTA) for PRD [13]. 
Alternatively, it could be done using existing generic clinical terminology lists, such as 
Systematised Nomenclature of Medicine – Clinical Terms (http://www.snomed.org/snomed-
ct), with back translation into groups of codes that are clinically relevant to nephrology. 
Further work needs to be done to shed more light on the causes of death in transplant 
recipients to identify ways to improve their long-term survival. 
Although not the focus of this work, an additional limitation is the paucity of donor data 
available for analysis. Specific data regarding immunosuppression regimes is also 
unavailable.  
 
CONCLUSION 
We have presented a detailed analysis of allograft outcomes in a large, national cohort of 
UK kidney transplant recipients to assess the changing causes of renal allograft failure in the 
era of modern immunosuppression. We note that there are fewer early graft losses in the 
most recent cohort of patients and fewer allograft failures due to alloimmune and surgical 
causes. Death with a functioning graft remains the leading cause of allograft failure beyond 
the first six months following transplantation. While on the one hand this may reflect the 
increasing age of kidney transplant recipients, this may also suggest that there is scope for 
better modification of cardiac risk factors and improved management of cardiac and 
infectious disease in transplanted patients. If routine data are to support hypothesis 
generating observational analyses or efficient registry trials in the future, codes and 
definitions for core outcomes such as cause of graft failure need to be agreed and 
implemented. 
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TABLES 
Box 1. Revised classification of causes of allograft failure  
Original cause of graft failure categories New cause of graft failure categories 
Hyperacute rejection 
Rejection while taking immunosuppressive drug(s) 
Rejection after stopping all immunosuppressive drug(s) 
Other 
Alloimmune pathology 
Recurrent primary renal disease 
Other 
Recurrent primary disease 
Vascular or ureteric operative problems 
Vascular (arterial or venous) thrombosis 
Other 
Surgical cause 
      Thrombosis 
      Vascular or ureteric operative problems (not thrombosis) 
Infection of graft 
Other 
Infection of graft 
Removal of functioning graft 
Other 
Removal of a functioning graft 
Non-viable kidney 
Other 
Non-viable kidney 
Recipient died, graft still functioning at time of death Death with a functioning graft 
Other Other 
      >1 cause stated 
      Acute kidney injury with non-recovery 
      Acute tubular necrosis 
      Biopsy related 
      Calcineurin inhibitor toxicity 
      De novo glomerulonephritis 
      Donor pathology 
      Drug related 
      Hypertensive/ischaemic 
      Infarcted kidney 
      Interstitial fibrosis/tubular atrophy 
      Interstitial nephritis 
      Malignancy (graft) 
      Malignancy (non-graft) 
      Miscellaneous 
      Mycotic aneurysm 
      Patient death 
      Post-transplant lymphoproliferative disease 
      Pregnancy 
      Primary non-function 
      Thrombotic microangiopathy 
      Transplant glomerulopathy 
Missing Missing 
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Table 1. Patient demographics for total follow-up time 
Patient demographics 
 
Total 
N=22,730 
Surviving Failed 
% or median (IQR) or 
mean (SD) 
N=17,341 
% or median (IQR) or 
mean (SD) 
N=5,389 
Age at transplantation 
      
<40 years 6,585 30.1 25.4 
40–54 years 8,473 39.3 30.8 
≥55 years 7,672 30.6 43.8 
Overall (mean [SD]) 22,730 47.3 (13.3) 50.7 (14.4) 
Recipient sex       
Male 13,978 61.3 62.3 
Female 8,752 38.8 37.7 
Recipient ethnicity      
Asian 2,268 10.1 9.7 
Black 1,273 5.5 5.9 
Other 469 2.2 1.5 
White 18,714 82.2 82.9 
Missing 6 0.0 0.0 
Pre-transplant modality      
Haemodialysis 12,406 52.6 60.9 
Peritoneal dialysis 6,226 27.0 28.6 
Pre-emptive transplant 4,063 20.2 10.4 
Unknown 35 0.2 0.2 
Time on dialysis      
<1 year 8,070 38.8 24.8 
1–3 years 7,252 31.3 33.9 
>3 years 7,408 29.9 41.3 
Overall (median [IQR]) 22,730 1.6 (0.3–3.5) 2.4 (1.0–4.5) 
Primary renal disease    
Diabetes 3,266 13.5 17.3 
Glomerulonephritis 4,970 22.0 21.5 
Hypertension 1,317 5.5 6.8 
Missing 633 2.8 2.6 
Other (high risk) 1,339 5.8 6.2 
Other (low risk) 2,098 9.5 8.3 
Polycystic disease 3,326 15.7 11.2 
Pyelonephritis 2,259 9.9 10.0 
Renal vascular disease 291 1.2 1.6 
Uncertain 3,231 14.1 14.6 
Donor type      
DBD 10,824 44.0 59.3 
DCD 4,423 19.7 18.6 
Live 7,483 36.3 22.2 
Donor age      
 17 
 
<40 years 6,443 30.1 22.7 
40–54 years 9,268 41.1 39.7 
≥55 years 7,008 28.7 37.6 
Missing 11 0.1 0.0 
Overall (mean [SD]) 22,719 46.2 (14.8) 49.6 (14.6) 
HLA mismatch      
0 0 0 2,535 11.2 11.1 
0DR & 0/1B  6,120 25.9 30.4 
0DR & 2B or 1DR & 0/1B  9,606 42.5 41.6 
1DR & 2B or 2DR 4,460 20.5 17.0 
Missing 9 0.1 0.0 
Cold ischaemic time (hours)      
Overall (median [IQR]) 21,892 12.3 (3.5–16.9) 15.1 (9.8–19.3) 
Missing 838   
IQR, interquartile range; SD, standard deviation; DBD, donors after brain death; DCD, donors after circulatory death; HLA, 
human leukocyte antigen  
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Table 2. Patient demographics by year of transplant for total follow-up time 
 
Patient demographics 
2000–2004 2005–2008 2009–2013 
N=4,601 
% or median 
(IQR) or mean 
(SD) 
N=6,482 
% or median 
(IQR) or mean 
(SD) 
N=11,647 
% or median 
(IQR) or mean 
(SD) 
Age at transplantation       
<40 years  1,626  35.3  2,096  32.3  2,863  24.6 
40–54 years  1,683  36.6  2,494  38.5  4,296  36.9 
≥55 years  1,292  28.1  1,892  29.2  4,488  38.5 
Overall (mean [SD])  4,601  46.1 (13.4)  6,482  46.6 (13.3)  11,647  49.8 (13.7) 
Recipient sex       
Male  2,788  60.6  3,941  60.8  7,249  62.2 
Female  1,813  39.4  2,541  39.2  4,398  37.8 
Recipient ethnicity       
Asian  294  6.4  579  8.9  1,395  12.0 
Black  159  3.5  360  5.6  754  6.5 
Other  71  1.5  123  1.9  275  2.4 
White  4,072  88.5  5,420  83.6  9,222  79.2 
Missing  5  0.1  -    1  0.0 
Pre-transplant modality       
Haemodialysis  2,291  49.8  3,518  54.3  6,597  56.6 
Peritoneal dialysis  1,779  38.7  1,850  28.5  2,597  22.3 
Pre-emptive transplant  516  11.2  1,102  17.0  2,445  21.0 
Unknown  15  0.3  12  0.2  8  0.1 
Time on dialysis       
<1 year  1,449  31.5  2,245  34.6  4,376  37.6 
1–3 years  1,867  40.6  1,993  30.8  3,392  29.1 
>3 years  1,285  27.9  2,244  34.6  3,879  33.3 
Overall (median [IQR])  4,601  1.8 (0.8–3.2)  6,482  1.8 (0.5–4.0)  11,647  1.8 (0.3–3.8) 
Primary renal disease       
Diabetes  583  12.7  992  15.3  1,691  14.5 
Glomerulonephritis  1,083  23.5  1,385  21.4  2,502  21.5 
Hypertension  256  5.6  330  5.1  731  6.3 
Missing  55  1.2  104  1.6  474  4.1 
Other (high risk)  279  6.1  376  5.8  684  5.9 
Other (low risk)  356  7.7  619  9.6  1,123  9.6 
Polycystic disease  693  15.1  931  14.4  1,702  14.6 
Pyelonephritis  539  11.7  714  11.0  1,006  8.6 
Renal vascular disease  57  1.2  82  1.3  152  1.3 
Uncertain  700  15.2  949  14.6  1,582  13.6 
Donor type       
DBD  3,178  69.1  3,173  49.0  4,473  38.4 
DCD  305  6.6  1,049  16.2  3,069  26.4 
Live  1,118  24.3  2,260  34.9  4,105  35.3 
Donor age       
<40 years  1,421  30.9  1,963  30.3  3,059  26.3 
40–54 years  1,954  42.5  2,772  42.8  4,542  39.0 
 19 
 
≥55 years  1,221  26.5  1,743  26.9  4,044  34.7 
Missing  5  0.1  4  0.1  2  0.0 
Overall (mean [SD])  4,596  45.6 (14.5)  6,478  45.6 (14.6)  11,645  48.4 (15.0) 
HLA mismatch       
0 0 0  591  12.9  781  12.1  1,163  10.0 
0DR & 0/1B  1,880  40.9  1,584  24.4  2,656  22.8 
0DR & 2B or 1DR & 0/1B  1,458  31.7  2,759  42.6  5,389  46.3 
1DR & 2B or 2DR  667  14.5  1,354  20.9  2,439  20.9 
Missing  5  0.1  4  0.1  -   
Cold ischaemic time 
(hours) 
      
Overall (median [IQR])  4,539  16.2 (9.5–20.2)  6,290  13.5 (3.2–17.9)  11,063  11.6 (4–16) 
Missing  62    192    584   
IQR, interquartile range; SD, standard deviation; DBD, donors after brain death; DCD, donors after circulatory death; HLA, 
human leukocyte antigen  
 
Table 3. Percentage distribution of causes of allograft failure according to recipient age group 
adjusted for sex (ref=male), PRD (ref=glomerulonephritis) and ethnicity (ref=White) for total 
follow-up time 
Age 
group 
(yrs) 
N Alloimmune 
pathology 
(%) 
Recurrent 
primary 
disease 
(%) 
Surgical 
cause 
(%) 
Infection 
of graft 
(%) 
Removal of 
a 
functioning 
graft (%) 
Non-
viable 
kidney 
(%) 
Death with 
a 
functioning 
graft (%) 
Missing 
(%) 
Other 
(%) 
<40  1,339 39.4 14.6 8.1 0.8 0.1 1.2 11.2 20.4 4.2 
40–54 1,616 27.4 8.9 8.2 0.9 1.1 2.1 31.4 16.0 4.1 
≥55 2,291 15.8 4.9 6.9 0.6 0.8 2.8 52.5 12.0 3.7 
Patients with missing data for PRD and ethnicity were excluded from the analysis 
 
Table 4. Percentage distribution of causes of allograft failure according to donor type adjusted for 
recipient age group (ref=40–54 years), sex (ref=male), PRD (ref=glomerulonephritis) and ethnicity 
(White) for total follow-up time 
Don
or 
type  
N Alloimmu
ne 
pathology 
(%) 
Recurre
nt 
primary 
disease 
(%) 
Surgical 
cause 
(%) 
Infection 
of graft 
(%) 
Removal 
of a 
functioni
ng graft 
(%) 
Non-
viable 
kidne
y (%) 
Death 
with a 
functioni
ng graft 
(%) 
Missing 
(%) 
Other 
(%) 
DBD 3,112 27.5 7.9 7.9 0.8 1.2 2.1 32.1 16.2 4.3 
DCD 978 25.2 7.0 10.9 1.0 1.7 3.2 30.0 16.2 4.9 
Live 1,156 28.2 12.6 7.3 1.1 0.5 1.4 30.4 15.4 3.2 
Patients with missing data for PRD and ethnicity were excluded from the analysis 
DBD, donors after brain death; DCD, donors after circulatory death 
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Table 5. Percentage distribution of causes of allograft failure according to ethnicity adjusted for 
recipient age group (40–54 years), sex (male) and PRD (glomerulonephritis) for total follow-up 
time 
Ethnici
ty 
N Alloimmu
ne 
pathology 
(%) 
Recurrent 
primary 
disease 
(%) 
Surgical 
cause 
(%) 
Infection 
of graft 
(%) 
Removal 
of a 
functioni
ng graft 
(%) 
Non-
viable 
kidne
y (%) 
Death 
with a 
functioni
ng graft 
(%) 
Missing 
(%) 
Other 
(%) 
White 4,344 27.4  8.9  8.2  0.9  1.1  2.1  31.4  16.0  4.1  
Black 311 32.9  8.8  10.8  3.7  2.0  6.4  20.9  8.9  5.6  
Asian 510 34.3  4.7  9.1  2.1  3.6  0.0  29.5  8.6  8.2  
Other 81 34.4  4.6  9.0  4.0  2.4  5.0  25.0  10.8  4.9  
Patients with missing data for PRD and ethnicity were excluded from the analysis 
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LEGENDS TO FIGURES 
Figure 1. Flow diagram detailing allograft outcomes for the entire study cohort 
Figure 2. Distribution of causes of allograft failure  
Figure 3. Distribution of causes of allograft failure at different time points post-transplantation 
adjusted for recipient age group (40–54 years), sex (male), PRD (glomerulonephritis) and ethnicity 
(White) 
Figure 4. Allograft failure within two years of transplantation across different transplant eras 
Figure 5. Distribution of causes of allograft failure across different transplant eras adjusted for 
recipient age group (40–54 years), sex (male), PRD (glomerulonephritis) and ethnicity (White) for 
two years follow-up 
Figure 6. Distribution of causes of allograft failure according to HLA mismatch adjusted for 
recipient age group (40–54 years), sex (male), PRD (glomerulonephritis) and ethnicity (White) 
Figure 7. Number of allograft failures by HLA type and transplant era 
 
 
  
 22 
 
Supplementary data 
Table S1. Sub-categorisation of failed grafts coded as ‘other’ 
Cause of graft failure N % 
>1 cause stated 33 12.4 
Acute kidney injury with non-recovery 39 14.7 
Acute tubular necrosis 4 1.5 
Biopsy related 1 0.4 
Calcineurin inhibitor toxicity 5 1.9 
De novo glomerulonephritis 2 0.8 
Donor pathology 10 3.8 
Drug related 1 0.4 
Hypertensive/ischaemic 10 3.8 
Infarcted kidney 7 2.6 
Interstitial fibrosis/tubular atrophy 52 19.6 
Interstitial nephritis 4 1.5 
Malignancy (non-graft) 3 1.1 
Miscellaneous 31 11.7 
Mycotic aneurysm 3 1.1 
Patient death 5 1.9 
Post-transplant lymphoproliferative disease 8 3.0 
Pregnancy 3 1.1 
Primary non-function 42 15.8 
Thrombotic microangiopathy 1 0.4 
Transplant glomerulopathy 2 0.8 
Total 266 100.0 
 
 
